Lancet Oncology
Painless skin rash predicts survival benefit from latest lung cancer drug, study finds
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, c ...
Cancer
Oct 17, 2012 |
not rated yet |
0
Study discovers gene signature that predicts prostate cancer survival
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October ...
Cancer
Oct 10, 2012 |
not rated yet |
0
New drug shrinks brain tumours in melanoma patients
(Medical Xpress)—Australian researchers have given hope to patients with advanced melanoma by showing that a new drug targeting a common mutation in melanoma successfully shrank tumours that had spread to the brain.
Cancer
Oct 08, 2012 |
not rated yet |
0
|
Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer ...
Cancer
Sep 17, 2012 |
not rated yet |
0
Study supports tobacco link to ovarian cancer
(Medical Xpress)—Researchers from Curtin University's School of Public Health have contributed to a comprehensive international study examining risk factors for ovarian cancer.
Cancer
Sep 12, 2012 |
not rated yet |
0
|
Drug trial offers hope to patients with advanced colorectal cancer
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in the Lancet Oncology.
Cancer
Aug 27, 2012 |
not rated yet |
0
Vandetanib almost doubles progression free survival in patients with thyroid cancer
Results of a phase 2 randomised trial for patients with advanced differentiated thyroid cancer (DTC) show that those treated with the oral targeted agent vandetanib survived without the disease getting worse for almost twice ...
Cancer
Aug 13, 2012 |
not rated yet |
0
New Herceptin delivery method could vastly simplify breast cancer treatment
A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in hospital for some women undergoing breast cancer treatment, according to the results of a Phase 3 trial published ...
Cancer
Aug 08, 2012 |
not rated yet |
0
Genetic markers hope for new brain tumor treatments
Researchers at The University of Nottingham have identified three sets of genetic markers that could potentially pave the way for new diagnostic tools for a deadly type of brain tumour that mainly targets children.
Cancer
Jun 15, 2012 |
5 / 5 (1) |
0
|
Blood test could lead to improved diagnosis and treatment of breast cancer
Scientists have discovered that a simple blood test could lead to better diagnosis and treatment for early-stage breast cancer patients, according to an Article published Online First in The Lancet Oncology.
Cancer
Jun 05, 2012 |
not rated yet |
0
Cancer incidence predicted to increase 75 percent by 2030
The global cancer burden is set to surge more than 75% by 2030, according to new research published Online First in the Lancet Oncology. The rise is predicted to be even larger in the developing world, with the poorest countr ...
Cancer
May 31, 2012 |
5 / 5 (2) |
0
|
Chemotherapy and radiation given together could help elderly patients with lung cancer live longer
Despite more than two-thirds of lung cancer cases being diagnosed in people 65 years or older, there have been few trials of treatments in this age group, and it is not known if the standard treatment for patients with inoperable ...
Cancer
May 21, 2012 |
not rated yet |
0
- Pages: 1 2
